Intermediate-term risk of cardiac allograft vasculopathy following heart transplantation from hepatitis C viremic donors in the era of direct-acting antiviral therapy

Figures

• 

  Figure 1. Median annual mean intimal thickness (MIT) following heart transplantation in recipients of HCV NAT− and HCV NAT+ donor hearts over 7 years of follow-up. Median MIT (in mm) is shown for each year post-transplant, with gray bars representing NAT− and blue bars representing NAT+ recipients. Error bars indicate interquartile range. # At year 7, no NAT+ recipients had available follow-up; therefore, only NAT− values are shown. No significant differences in median annual MIT were observed between groups at any time point.

• 

  Figure 2. Proportion of intravascular ultrasound (IVUS) studies demonstrating significant intimal thickening in recipients of HCV NAT− and HCV NAT+ donor hearts over 7 years of follow-up. (A) Percentage of IVUS studies with mean intimal thickness (MIT) ≥ 0.5 mm. (B) Percentage of IVUS studies with MIT ≥ 0.7 mm. Gray bars represent NAT− recipients; blue bars represent NAT+ recipients. # At year 7, no NAT+ recipients had available follow-up; therefore, only NAT− values are shown. No statistically significant differences were observed between groups at any time point.

• 

  Figure 3. Kaplan-Meier curves comparing outcomes in recipients of HCV NAT− and HCV NAT+ donor hearts, with the number at risk listed below each graph. (A) Cumulative probability of developing cardiac allograft vasculopathy (CAV), defined as mean intimal thickness (MIT) ≥ 0.5 mm. (B) Cumulative probability of developing CAV with a more restrictive threshold of MIT ≥ 0.7 mm. (C) Event-free survival for the composite outcome of acute coronary syndrome (NSTEMI or STEMI), percutaneous coronary intervention (PCI), or all-cause mortality. Gray lines represent NAT− recipients; blue lines represent NAT+ recipients. Log-rank p-values: 0.880 (A), 0.535 (B), and 0.193 (C). No statistically significant differences were observed.